This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welsch, J. A.
Right arrow Articles by Granoff, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welsch, J. A.
Right arrow Articles by Granoff, D.

 Previous Article  |  Next Article 

Infection and Immunity, October 2004, p. 5903-5909, Vol. 72, No. 10
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.10.5903-5909.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Naturally Acquired Passive Protective Activity against Neisseria meningitidis Group C in the Absence of Serum Bactericidal Activity

Jo Anne Welsch and Dan Granoff*

Children's Hospital Oakland Research Institute, Oakland, California

Received 26 March 2004/ Returned for modification 3 May 2004/ Accepted 27 May 2004

The hallmark of immunity to meningococcal disease is a bactericidal titer in serum of ≥1:4 measured with human complement, but this threshold titer may underestimate the extent of protection. We used the infant rat model of meningococcal bacteremia to measure group C passive protective activity in serum samples from 91 unimmunized adults living in California. A total of 35 sera (38.5%) had passive protective activity. Sera with complement-mediated bactericidal titers of ≥1:4 were 3.4-fold more likely to confer protection (89%) than nonbactericidal sera (26%; P < 0.0001). Thus, bactericidal titers of ≥1:4 are a marker of protection, but this threshold lacks sensitivity for predicting protective activity. We investigated the 73 sera with bactericidal titers of <1:4 to determine the basis of protective activity. The 19 sera with protective activity had a higher geometric mean group C anticapsular antibody concentration (0.72 µg/ml) than the 54 sera that lacked protective activity (0.16 µg/ml; P < 0.001). Thus, protective activity in the absence of bactericidal activity was associated with higher concentrations of anticapsular antibodies, but not all sera with anticapsular antibodies conferred protection. Of 18 nonbactericidal sera with anticapsular antibody concentrations between 0.31 and 0.99 µg/ml, the 11 sera that conferred protection had a higher mean antibody avidity constant (21.9 nM–1) than the 7 nonprotective sera (14.6 nM–1; P < 0.03). Thus, in sera with titers of <1:4, protective activity is associated with higher-avidity group C anticapsular antibodies, which are present in concentrations insufficient to elicit complement-mediated bacteriolysis in vitro but sufficient to confer protection in an in vivo bacteremia model.

* Corresponding author. Mailing address: 5700 Martin Luther King Jr. Way, Oakland, CA 94609. Phone: (510) 450-7640. Fax: (510) 450-7915. E-mail: dgranoff{at}chori.org.

Editor: D. L. Burns

Infection and Immunity, October 2004, p. 5903-5909, Vol. 72, No. 10
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.10.5903-5909.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gorringe, A. R., Taylor, S., Brookes, C., Matheson, M., Finney, M., Kerr, M., Hudson, M., Findlow, J., Borrow, R., Andrews, N., Kafatos, G., Evans, C. M., Read, R. C. (2009). Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on Neisseria lactamica Outer Membrane Vesicles. CVI 16: 1113-1120 [Abstract] [Full Text]  
  • Plested, J. S., Welsch, J. A., Granoff, D. M. (2009). Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity. CVI 16: 785-791 [Abstract] [Full Text]  
  • Foster, R. A., Carlring, J., McKendrick, M. W., Lees, A., Borrow, R., Read, R. C., Heath, A. W. (2009). Evidence of a Functional B-Cell Immunodeficiency in Adults Who Experience Serogroup C Meningococcal Disease. CVI 16: 692-698 [Abstract] [Full Text]  
  • Granoff, D. M., Welsch, J. A., Ram, S. (2009). Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera. Infect. Immun. 77: 764-769 [Abstract] [Full Text]  
  • Beernink, P. T., Welsch, J. A., Bar-Lev, M., Koeberling, O., Comanducci, M., Granoff, D. M. (2008). Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein. Infect. Immun. 76: 4232-4240 [Abstract] [Full Text]  
  • Uria, M. J., Zhang, Q., Li, Y., Chan, A., Exley, R. M., Gollan, B., Chan, H., Feavers, I., Yarwood, A., Abad, R., Borrow, R., Fleck, R. A., Mulloy, B., Vazquez, J. A., Tang, C. M. (2008). A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. JEM 205: 1423-1434 [Abstract] [Full Text]  
  • Tsai, T. F., Borrow, R., Gnehm, H. E., Vaudaux, B., Heininger, U., Desgrandchamps, D., Aebi, C., Balmer, P., Pedersen, R. D., Fritzell, B., Siegrist, C.-A. (2006). Early Appearance of Bactericidal Antibodies after Polysaccharide Challenge of Toddlers Primed with a Group C Meningococcal Conjugate Vaccine: What Is Its Role in the Maintenance of Protection?. CVI 13: 854-861 [Abstract] [Full Text]  
  • Toropainen, M., Saarinen, L., Vidarsson, G., Kayhty, H. (2006). Protection by Meningococcal Outer Membrane Protein PorA-Specific Antibodies and a Serogroup B Capsular Polysaccharide-Specific Antibody in Complement-Sufficient and C6-Deficient Infant Rats. Infect. Immun. 74: 2803-2808 [Abstract] [Full Text]  
  • Harrison, L. H. (2006). Prospects for Vaccine Prevention of Meningococcal Infection. Clin. Microbiol. Rev. 19: 142-164 [Abstract] [Full Text]  
  • Toropainen, M., Saarinen, L., Wedege, E., Bolstad, K., Michaelsen, T. E., Aase, A., Kayhty, H. (2005). Protection by Natural Human Immunoglobulin M Antibody to Meningococcal Serogroup B Capsular Polysaccharide in the Infant Rat Protection Assay Is Independent of Complement-Mediated Bacterial Lysis. Infect. Immun. 73: 4694-4703 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»